Johns Hopkins Lipid Program — Ciccarone Center for the Prevention of Cardiovascular Disease

The Johns Hopkins Lipid Program, part of the Ciccarone Center for the Prevention of Cardiovascular Disease, exemplifies what academic medical center-level lipid expertise offers. This is the appropriate referral destination for patients whose lipid complexity has outpaced primary care management — those with familial hypercholesterolemia, severely elevated Lp(a), statin intolerance requiring alternative lipid-lowering strategies, or complex dyslipidemia with comorbidities that standard protocols do not adequately address.

The program offers the full spectrum of specialist lipid management: comprehensive evaluation, genetic screening for inherited disorders, detailed lipid testing including advanced markers that are not standard in community practice, personalized pharmacotherapy including PCSK9 inhibitors and emerging agents, and access to clinical trials. The multidisciplinary structure — cardiologists, dietitians, genetic counselors, specialty pharmacy — is relevant because the most complex lipid cases require more than prescription adjustment.

Lp(a) management is an emerging focus at programs like Hopkins, reflecting the expanding clinical landscape: several Lp(a)-lowering agents are in late-stage trials, and patients identified with significantly elevated Lp(a) now have a reason to establish care with a specialist who can enroll them in trials or initiate newly approved therapy when it becomes available. Hopkins’s research infrastructure makes it a logical site for this.

Prior authorization support for PCSK9 inhibitors — a practical impediment that many community physicians are unfamiliar with navigating — is explicitly offered. This administrative function has real clinical impact: PCSK9 inhibitor prescriptions are denied at initial prior authorization at high rates, and persistence through the appeals process requires institutional familiarity with the documentation requirements.

We rate the evidence moderate. The Johns Hopkins Lipid Program provides academic-center expertise in genetic lipid disorders, Lp(a) management, statin intolerance, and PCSK9 inhibitor access — the appropriate referral destination for patients whose lipid complexity requires beyond-primary-care management.